KPV vs LL-37
Emerging vs Well Studied
synergistic Complementary antimicrobial and healing effects.
Molecular Data
KPV LL-37
Half-life 1-2 hours Short (rapid proteolytic degradation)
Chain 3 amino acids 37 amino acids
Type Tripeptide Cationic antimicrobial peptide
Key Benefits
KPV
01 Systemic anti-inflammatory effects
02 No pigmentation/tanning effects
03 Immune modulation without immunosuppression
04 Potential for autoimmune conditions
05 Gut health support
06 Multiple delivery routes available
LL-37
01 Direct wound healing acceleration
02 Broad-spectrum antimicrobial activity
03 Activity against resistant bacteria (MRSA, MDRPA)
04 Enhanced tissue regeneration
05 Immune modulation
06 Local antimicrobial protection
Dosing Protocols
KPV
200-500 mcg per injection / 1-2 times daily (once for maintenance, twice for active inflammation)
General anti-inflammatory 200-300mcg Once daily
Active inflammation 250mcg Twice daily
Autoimmune support 500mcg Once daily
Acute flare-ups 500mcg 2x daily for 1 week, then reduce
LL-37
0.5-1.6 mg/mL topical gel or 100-150 mcg injectable / Topical: Daily to twice weekly on wounds. Injectable: Once daily subcutaneous
Systemic immune support 100-150mcg Once daily
Side Effects
KPV
Minimal to no side effects reported
Does not cause immunosuppression like steroids
No melanin production/tanning effects
May temporarily reduce inflammation-related symptoms
LL-37
Generally well-tolerated
Mild injection site reactions (injectable)
Local irritation at application site (topical)
Contraindications
Known peptide allergies
Active severe infections (theoretical)
Pregnancy or breastfeeding (limited data)
Pre-existing hypersensitivity to peptides
Compromised immune status (relative contraindication)
Non-sterile wound environments
Research Evidence
KPV LL-37
Status Emerging Well Studied
References 4 studies 4 studies
Latest March 2024 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.